ALN-PNP

Phase 2Small molecule

ALN-PNP is one of 56 small molecule programs targeting Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Recruiting

Liver DiseaseRecruiting

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Phase 2

Recruiting

Liver DiseasePhase 1

Recruiting

Competition

Competitive Landscape

100 competitors in Liver Disease

#DrugCompanyPhaseTrials

Balversa

Cibinqo

Dayvigo

Nourianz

Kyowa Kirin Co., Ltd.

Fabhalta

Rydapt

Lenvima

Opzelura

Lazcluze

Norvir

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Liver Disease

NCT05648214

Q1 2030

Phase 2Recruiting

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT07527910

Clinical

Trials by Indication[1]

Liver Disease1 trial

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Recruiting· Regeneron logo

Regeneron·Phase 1·NCT05648214·156 enrolled

Alcoholic Fatty Liver Disease1 trial

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

Completed· Regeneron logo

Regeneron·Phase 1·NCT06024408·9 enrolled

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)1 trial

A Two-Part, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of ALN-PNP With and Without a GLP1R Agonist in Adults With Homozygous PNPLA3-Related Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT07527910·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ALN-PNP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALN-PNP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALN-PNP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Regeneron

ALN-PNP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2030

Trials by Indication[1]

Liver Disease1 trial

Alcoholic Fatty Liver Disease1 trial

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)1 trial

References

Drug Info

Quick Facts

Related News